(Reuters) - U.S. specialty drugmaker Allergan Inc said late on Tuesday that it would buy MAP Pharmaceuticals Inc for about $958 million in cash, to deepen its presence in the treatment of migraines in adults.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment